Literature DB >> 1299465

Quality of life consequences of chemotherapy-induced emesis.

C M Lindley1, J D Hirsch, C V O'Neill, M C Transau, C S Gilbert, J T Osterhaus.   

Abstract

Nausea and vomiting following chemotherapy administration are common and often overlooked causes of impairment in cancer patients. The goal of this study was to explore the broad range of consequences associated with this specific acute toxicity of chemotherapy. Specific objectives were: (1) create and test scales specifically designed to assess the impact of chemotherapy-induced nausea and vomiting or patients' daily function; (2) examine changes in quality of life of cancer patients 3 days following chemotherapy administration; (3) assess the impact of chemotherapy-induced emesis on quality of life and patients' daily function; (4) identify medical and non-medical cost-related consequences associated with chemotherapy-induced emesis. Patients receiving intermittent bolus chemotherapy regimens on an outpatient basis were eligible for this survey. Four instruments were used: a patient maintained diary, the Functional Living Index-Cancer (FLIC), a newly created Functional Living Index-Emesis (FLIE) and an Item Check list for cost-related consequences. On Day 1, before chemotherapy, patients completed the FLIC and FLIE. Patients recorded episodes on vomiting, severity of nausea, anxiety, sedation, antiemetics self-administered, and adverse effects in diaries for 3 days following chemotherapy. The FLIC and FLIE were completed at the end of Day 3. The Item Check list of cost-related consequences was administered as a telephone survey on Day 5. Approximately 56% of 122 patients reported chemotherapy-induced emesis (CIE). A change in mean FLIC score indicating a decline in quality of life was observed for the CIE group (119 to 101) but not in the group who did not report emesis (124 to 122). Decline in FLIC and FLIE from before to after chemotherapy administration was greater for CIE patients (p = 0.001). FLIE scores indicated that CIE patients perceived that vomiting, and to a slightly lesser extent, nausea substantively influenced their ability to complete household tasks, enjoy meals, spend time with family and friends, and maintain daily function and recreation. Effect size calculations supported a significant negative relationship between occurrence of CIE and the direction and magnitude of functional living index change. An exploratory analysis (principal component followed by regression analysis) supported the hypothesis that side-effects produced by chemotherapy and antiemetic therapy significantly contributed to changes in quality of life observed.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1299465     DOI: 10.1007/bf00434947

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  4 in total

1.  Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population.

Authors:  C M Lindley; S Bernard; S M Fields
Journal:  J Clin Oncol       Date:  1989-08       Impact factor: 44.544

2.  Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation.

Authors:  H Schipper; J Clinch; A McMurray; M Levitt
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

3.  On the receiving end--patient perception of the side-effects of cancer chemotherapy.

Authors:  A Coates; S Abraham; S B Kaye; T Sowerbutts; C Frewin; R M Fox; M H Tattersall
Journal:  Eur J Cancer Clin Oncol       Date:  1983-02

4.  Nausea and vomiting as major complications of cancer chemotherapy.

Authors:  J Laszlo
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

  4 in total
  67 in total

Review 1.  Stratified administration of serotonin 5-HT3 receptor antagonists (setrons) for chemotherapy-induced emesis. Economic implications.

Authors:  L A Sanchez; M Holdsworth; S B Bartel
Journal:  Pharmacoeconomics       Date:  2000-12       Impact factor: 4.981

Review 2.  Measuring the effect of cancer on health-related quality of life.

Authors:  D Osoba
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

3.  Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy.

Authors:  Rahat Noor; Agop Y Bedikian; Sandy Mahoney; Roland Bassett; Kevin Kim; Nicholas Papadopoulos; Wen-Jen Hwu; Patrick Hwu; Jade Homsi
Journal:  Support Care Cancer       Date:  2012-01-25       Impact factor: 3.603

4.  The impact of chemotherapy-induced nausea and vomiting on health-related quality of life.

Authors:  Enzo Ballatori; Fausto Roila; Benedetta Ruggeri; Maura Betti; Samanta Sarti; Giancarla Soru; Giorgio Cruciani; Massimo Di Maio; Biffi Andrea; Robert R Deuson
Journal:  Support Care Cancer       Date:  2006-08-29       Impact factor: 3.603

Review 5.  A review of patient self-report tools for chemotherapy-induced nausea and vomiting.

Authors:  Sarah G Brearley; Caroline V Clements; Alex Molassiotis
Journal:  Support Care Cancer       Date:  2008-06-13       Impact factor: 3.603

Review 6.  Aprepitant: a review of its use in the prevention of nausea and vomiting.

Authors:  Monique P Curran; Dean M Robinson
Journal:  Drugs       Date:  2009       Impact factor: 9.546

7.  Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool.

Authors:  Yuka Matsuda; Kenji Okita; Tomohisa Furuhata; Goro Kutomi; Kentaro Yamashita; Yasushi Sato; Rishu Takimoto; Koichi Hirata
Journal:  Support Care Cancer       Date:  2015-05-24       Impact factor: 3.603

8.  Aprepitant and granisetron for the prophylaxis of radiotherapy-induced nausea and vomiting after moderately emetogenic radiotherapy for bone metastases: a prospective pilot study.

Authors:  K Dennis; C De Angelis; F Jon; N Lauzon; M Pasetka; L Holden; E Barnes; C Danjoux; A Sahgal; M Tsao; E Chow
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

9.  Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy.

Authors:  Imad Treish; Stacy Shord; John Valgus; Donald Harvey; Jessica Nagy; Jennifer Stegal; Celeste Lindley
Journal:  Support Care Cancer       Date:  2003-06-27       Impact factor: 3.603

10.  Risk factors of chemotherapy-induced nausea and vomiting in patients with metastatic colorectal cancer: a prospective cohort study (YCOG1301).

Authors:  Shogo Takei; Atsushi Ishibe; Jun Watanabe; Kazuteru Watanabe; Yusuke Suwa; Shinsuke Suzuki; Kazuya Nakagawa; Hirokazu Suwa; Mitsuyoshi Ota; Yasushi Ichikawa; Chikara Kunisaki; Takeharu Yamanaka; Itaru Endo
Journal:  Int J Colorectal Dis       Date:  2020-08-28       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.